หน้าแรก
ค้นหา
Dr. Petrylak on Immunotherapy for Second-line Treatment in Bladder Cancer
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Petrylak on Immunotherapy for Second-line Treatment in Bladder Cancer
Dr. Petrylak on Immunotherapy in Bladder Cancer
Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer
Daniel P. Petrylak, MD, on immunotherapy & chemotherapy combinations in metastatic bladder cancer
Updates on Immunotherapy for Bladder Cancer
Dr. Petrylak on Combinations with Pembrolizumab in Urothelial Carcinoma
Dr. Daniel Petrylak on the IMvigor Study of Atezolizumab in Advanced Bladder Cancer
Treatment of Bladder Cancer-Immune Checkpoint Inhibitors
Evaluating Second-Line Treatment Options in Bladder Cancer
Bladder Cancer: Real-World Experience With Immunotherapy
Dr Daniel Petrylak Explains PD-1, PD-L1 Expression in Bladder Cancer Treatment
Bladder Cancer and Immunotherapy
Advanced/Metastatic Urothelial Carcinoma: Understanding Novel Immunotherapy Maintenance Strategies
Chemotherapy Following Immunotherapy in Bladder Cancer
Historic Perspective on Treatment of Bladder Cancer
The Latest on Men's Cancer - Part 2: Bladder Cancer
Dr. Balar on Immunotherapy Treatment in Bladder Cancer
Dr. Galsky on Progression on Immunotherapy in Bladder Cancer
Case 2: Combination Therapy for Cis-Ineligible Bladder Cancer
Update on Durvalumab for Metastatic Bladder Cancer
